May/June 2023

Featured Article

Research Reports

Can We Fill in the Gaps? Authoring Custom Oncology Pathways vs Surfacing NCCN Preferred Recommendations Alone

06/05/2023

Rebecca Maniago, PharmD, BCOP

Marcello Ricottone

Gregory S. Calip, PharmD, MPH, PhD

Taylor Dias-Foundas

James Hamrick, MD, MPH

Rebecca Maniago, PharmD, and colleagues compare the overall availability of NCCN Preferred recommendations to custom preferred pathways and assess provider concordance with the preferred suggestions, particularly those encountered in the...

Rebecca Maniago, PharmD, and...

06/05/2023

Journal of Clinical Pathways

Research Reports

Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer

06/05/2023

Emma L. Barber, MD

Allison M. Saiz, MD

Nicole M. Engel-Nitz, PhD

Scott H. Bunner, MPH

Katrine L. Wallace, PhD

Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.

Emma L. Barber, MD, and...

06/05/2023

Journal of Clinical Pathways

Research Reports

Pegfilgrastim Home Redirection Outcomes: Effectiveness and Timing of Administration in Primary Prophylaxis of Chemotherapy-Induced Neutropenia

06/05/2023

Lavanya Raj, MBBS, MS

Pam McManus

Lavanya Raj, MBBS, MS, and Pam McManus summarize the impact of Cigna’s site-of-care home-redirection program on pegfilgrastim effectiveness and the timing of administration in preventing complications from chemotherapy-induced neutropenia...

Lavanya Raj, MBBS, MS, and Pam...

06/05/2023

Journal of Clinical Pathways

Editor's Page

A New Beginning and a Look at the Real World

06/05/2023

Winston Wong, PharmD, Editor-in-Chief

Editor-in-Chief, Winston Wong, PharmD, contextualizes this issue’s content and introduces a new column, Transformative Employer Trends, managed by F. Randy Vogenberg, PhD, which will focus on the employer perspective related to various...

Editor-in-Chief, Winston Wong,...

06/05/2023

Journal of Clinical Pathways

Column

Trending From ACCC

Barriers to Treating Patients With Small Cell Lung Cancer: Findings from a Survey of Patients and Providers

06/05/2023

American Association of Community Cancer Centers

This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...

This column describes the...

06/05/2023

Journal of Clinical Pathways

Transformative Employer Trends

Employer Commercial Insurance Landscape

06/05/2023

F. Randy Vogenberg, PhD, FASHP

This first installment of the new “Transformative Employer Trends” column explores the employer’s perspective when it comes to utilizing and developing pathways of care, including how they manage risk, their care plans and strategies, and...

This first installment of the...

06/05/2023

Journal of Clinical Pathways

COA Viewpoint

A Commonsense Solution to Medicare Reimbursement

06/05/2023

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

Nicolas Ferreyos from the Community Oncology Alliance discusses the Strengthening Medicare for Patients and Providers Act (HR 2474) and what it means for both physicians and patients on Medicare.

Nicolas Ferreyos from the...

06/05/2023

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

May/June 2023

Featured Article

Column

Current Issue

Special Reports

Subscribe

June 2023 Volume 9 Issue 3

Specialties

Events

Year Round Education

HMP Global Products